デフォルト表紙
市場調査レポート
商品コード
1611831

破傷風トキソイドワクチン市場:ワクチンタイプ、年齢、エンドユーザー別-2025-2030年世界予測

Tetanus Toxoid Vaccine Market by Vaccine Type (Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), Tetanus, Diphtheria and Pertussis (Tdap)), Age (Adults, Neonatal), End User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 193 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
破傷風トキソイドワクチン市場:ワクチンタイプ、年齢、エンドユーザー別-2025-2030年世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

破傷風トキソイドワクチン市場は、2023年に55億8,000万米ドルと評価され、2024年には58億6,000万米ドルに達すると予測され、CAGR 6.75%で成長し、2030年には88億3,000万米ドルに達すると予測されています。

破傷風トキソイドワクチンは、筋肉の硬直と痙攣を特徴とする致命的な細菌感染症である破傷風を予防する能力によって定義される重要な医療製品です。このワクチンの必要性は、特にヘルスケア施設や軍隊、開発途上地域での出産時など、切り傷や怪我を負い、クロストリジウム・テタニ(Clostridium tetani)にさらされる可能性のある人々を保護する役割に由来します。その用途は様々な公衆衛生プログラムにも及び、そこでは定期的な予防接種とブースター注射が極めて重要です。このワクチンの最終用途には、病院、クリニック、地域ヘルスケア・サービスなどが含まれ、中低所得国での利用拡大が大きく推進されています。現在の破傷風トキソイドワクチン市場は、予防接種に対する世界の意識の高まり、政府による支援的な予防接種プログラム、送達技術の進歩といった要因の影響を受けています。複数の疾病を予防する混合ワクチンに注目が集まっており、メーカーが技術革新を図り、多様な人口動態に対応する道が開かれつつあります。しかし、ワクチン配送におけるロジスティクスの問題、遠隔地における認識不足、特定の集団におけるワクチン接種のためらいといった課題に直面しています。さらに、手頃な価格のヘルスケアソリューションが求められる中、規制上のハードルや価格圧力が市場の抑制要因となっています。このような課題にもかかわらず、革新の余地がある分野には、単回投与ワクチン、コールドチェーン技術の改善、効率と接種率を高めるデジタル制御の送達システムなどがあります。同市場は、公衆衛生上の優先事項や、接種率を高めるための非政府組織との協力関係によって、安定的かつ弾力的な成長パターンに傾いています。企業は、教育キャンペーンへの投資や、より広く一般に受け入れられやすい、費用対効果が高く投与が容易なワクチンの開発によって利益を得ることができます。

主な市場の統計
基準年[2023] 55億8,000万米ドル
推定年[2024] 58億6,000万米ドル
予測年[2030] 88億3,000万米ドル
CAGR(%) 6.75%

市場力学:急速に進化する破傷風トキソイドワクチン市場の主要市場インサイトを公開

破傷風トキソイドワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の破傷風の著しい流行
    • 破傷風ワクチンの低コスト化と幅広い入手可能性
  • 市場抑制要因
    • ワクチンの品質欠陥による製品回収の可能性
  • 市場機会
    • 啓発および予防接種プログラムに対する政府の取り組み
    • 各国のコールドチェーンとヘルスケアインフラの改善
  • 市場の課題
    • ワクチンに伴う副作用

ポーターのファイブフォース破傷風トキソイドワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:破傷風トキソイドワクチン市場における外部からの影響の把握

外部マクロ環境要因は、破傷風トキソイドワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析破傷風トキソイドワクチン市場における競合情勢の把握

破傷風トキソイドワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス破傷風トキソイドワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、破傷風トキソイドワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨破傷風トキソイドワクチン市場における成功への道筋を描く

破傷風トキソイドワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で破傷風が蔓延している
      • 破傷風ワクチンは安価で広く入手可能
    • 抑制要因
      • ワクチンの品質欠陥による製品回収の可能性
    • 機会
      • 啓発および予防接種プログラムに関する政府の取り組み
      • 各国のコールドチェーンとヘルスケアインフラの改善
    • 課題
      • ワクチンに伴う副作用
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 破傷風トキソイドワクチン市場ワクチンの種類別

  • ジフテリアと破傷風(DT)
  • ジフテリア・破傷風・百日咳(DTaP)
  • 破傷風・ジフテリア・百日咳(Tdap)

第7章 破傷風トキソイドワクチン市場年齢別

  • 大人
  • 新生児

第8章 破傷風トキソイドワクチン市場:エンドユーザー別

  • クリニック
  • 病院

第9章 南北アメリカの破傷風トキソイドワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の破傷風トキソイドワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの破傷風トキソイドワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • AJ Vaccines A/S
  • Astellas Pharma Inc.
  • BB-NCIPD Ltd.
  • Bharat Biotech Ltd.
  • Bio Farma
  • Biological E. Limited
  • Dano Vaccines & Biologicals Pvt. Ltd.
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Vaccine Ltd.
  • MEDZEEL LIFESCIENCE
  • Merck & Co, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
図表

LIST OF FIGURES

  • FIGURE 1. TETANUS TOXOID VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. TETANUS TOXOID VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TETANUS TOXOID VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TETANUS TOXOID VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA AND TETANUS (DT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA,TETANUS, AND PERTUSSIS (DTAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY TETANUS, DIPHTHERIA AND PERTUSSIS (TDAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-B1685377AB26

The Tetanus Toxoid Vaccine Market was valued at USD 5.58 billion in 2023, expected to reach USD 5.86 billion in 2024, and is projected to grow at a CAGR of 6.75%, to USD 8.83 billion by 2030.

The Tetanus Toxoid Vaccine is a crucial medical product defined by its ability to prevent tetanus, a potentially fatal bacterial infection characterized by muscle stiffness and spasms. The necessity of the vaccine stems from its role in safeguarding individuals who suffer cuts, wounds, or injuries that may expose them to Clostridium tetani, especially in healthcare facilities, military units, and during childbirth in developing regions. Its application extends to various public health programs, where it is crucial for routine immunizations and booster shots. The end-use scope of the vaccine encompasses hospitals, clinics, and community healthcare services, with a significant push towards increasing access in low- and middle-income countries. The current market for the tetanus toxoid vaccine is influenced by factors such as increasing global awareness of immunization, supportive government vaccination programs, and advancements in delivery technologies. Opportunities are blooming with the rising focus on combination vaccines that protect against multiple diseases, presenting avenues for manufacturers to innovate and reach diverse demographics. However, market growth faces challenges such as logistical issues in vaccine delivery, lack of awareness in remote areas, and vaccine hesitancy in certain populations. Additionally, the market is constrained by regulatory hurdles and pricing pressures amidst the need for affordable healthcare solutions. Despite these challenges, areas ripe for innovation include single-dose vaccines, improved cold chain technologies, and digitally controlled delivery systems that enhance efficiency and coverage. The nature of the market tilts towards a stable yet resilient growth pattern, driven by public health priorities and collaborations with non-governmental organizations to boost inoculation rates. Businesses stand to gain by investing in educational campaigns and developing cost-effective, easy-to-administer vaccines for broader reach and heightened public acceptance.

KEY MARKET STATISTICS
Base Year [2023] USD 5.58 billion
Estimated Year [2024] USD 5.86 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 6.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tetanus Toxoid Vaccine Market

The Tetanus Toxoid Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant prevalence of tetanus worldwide
    • Low cost and wide availability of tetanus vaccine
  • Market Restraints
    • Potential product recall due to vaccine quality defects
  • Market Opportunities
    • Government initiatives for awareness and immunization programs
    • Improving cold chain and healthcare infrastructure across countries
  • Market Challenges
    • Side effects associated with vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Tetanus Toxoid Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tetanus Toxoid Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tetanus Toxoid Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tetanus Toxoid Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tetanus Toxoid Vaccine Market

A detailed market share analysis in the Tetanus Toxoid Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tetanus Toxoid Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tetanus Toxoid Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tetanus Toxoid Vaccine Market

A strategic analysis of the Tetanus Toxoid Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tetanus Toxoid Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Astellas Pharma Inc., BB-NCIPD Ltd., Bharat Biotech Ltd., Bio Farma, Biological E. Limited, Dano Vaccines & Biologicals Pvt. Ltd., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd., Incepta Vaccine Ltd., MEDZEEL LIFESCIENCE, Merck & Co, Inc., Panacea Biotec Limited, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Tetanus Toxoid Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), and Tetanus, Diphtheria and Pertussis (Tdap).
  • Based on Age, market is studied across Adults and Neonatal.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of tetanus worldwide
      • 5.1.1.2. Low cost and wide availability of tetanus vaccine
    • 5.1.2. Restraints
      • 5.1.2.1. Potential product recall due to vaccine quality defects
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives for awareness and immunization programs
      • 5.1.3.2. Improving cold chain and healthcare infrastructure across countries
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tetanus Toxoid Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Diphtheria and Tetanus (DT)
  • 6.3. Diphtheria,Tetanus, and Pertussis (DTaP)
  • 6.4. Tetanus, Diphtheria and Pertussis (Tdap)

7. Tetanus Toxoid Vaccine Market, by Age

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Neonatal

8. Tetanus Toxoid Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Tetanus Toxoid Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tetanus Toxoid Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tetanus Toxoid Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AJ Vaccines A/S
  • 2. Astellas Pharma Inc.
  • 3. BB-NCIPD Ltd.
  • 4. Bharat Biotech Ltd.
  • 5. Bio Farma
  • 6. Biological E. Limited
  • 7. Dano Vaccines & Biologicals Pvt. Ltd.
  • 8. GlaxoSmithKline PLC
  • 9. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 10. Incepta Vaccine Ltd.
  • 11. MEDZEEL LIFESCIENCE
  • 12. Merck & Co, Inc.
  • 13. Panacea Biotec Limited
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited